|
NKEA Grants to Promote Oleoderivatives and Food & Health Products (EPP* 6 & 8) |
 |
 |
 |
|
*Entry Point Project, Palm Oil National Key Economic Area
| GRANTS AVAILABLE |
| 1. |
Commercialization Grant for the Development of Oleo-Derivatives (EPP 6) |
| 2. |
Commercialization Grant for the Development of Food and Health-based Products (EPP8)
|
| 3. |
Clinical research on the nutritional benefits of palm oil and its phytonutrients (EPP 8) |
| |
| DESCRIPTION OF GRANT |
| To encourage production and development of oleo-derivatives, food and health-based products as well as to support the clinical trial research on the nutritional benefits of palm oil and its phytonutrients |
| PRODUCT SCOPE / SCOPE OF ACTIVITY |
a. Oleo derivatives (EPP6): |
| i. |
Surfactants |
| ii. |
Agrochemicals |
| iii. |
Bio-lubricants |
| iv. |
Bio-polyols |
| v. |
Glycerol derivatives |
| vi. |
Bio-based chemicals |
b. Food & Health-based Products (EPP8): |
| i. |
Palm-based food products with inclusion of high value-added phytonutrients (T3 or carotene) from existing product lines |
| ii. |
Commercial production of palm-based phytonutrients (carotene, tocotrienol, phenolics) |
| iii. |
Expansion of the existing facilities for high-value palm-based food products for export purposes |
| iv. |
Palm-based drinks |
| v. |
Red palm oil products |
| vi. |
Palm pressed fibre oil |
|
c. Lipid nutrition research or red palm oil or palm phytonutrient research covering any of the following areas (EPP 8):
|
| i. |
Renal disease |
| ii. |
Neuroprotection |
| iii. |
Arthritis |
| iv. |
Cardiovascular diseases |
| v. |
Cancer |
| vi. |
Fatty liver disease |
| vii. |
Macular degeneration |
| viii. |
Pancreatic disease |
| ix. |
Radioprotection |
| x. |
Children Nutrition |
| ELIBILITY CRITERIA AND OBLIGATIONS |
| |
|
| (A) |
Commercialization Projects: |
| |
Criteria for Large Companies (Beyond SME): |
| |
|
|
| |
|
|
| |
Criteria for SME :
|
| |
|
-
SMEs must be entities registered with SSM or other equivalent bodies, particularly local authorities or district offices in Sabah or Sarawak
-
SMEs are defined as firms with sales turnover not exceeding RM50 mil OR number of full-time employees not exceeding 200
- Products must have at least 25% value addition according to MIDA's definition
- Malaysia equity of at least 60%, not including PR
|
| |
|
|
| |
Obligations: |
| |
|
-
Delivery company effective Malaysian equity should remain the same or more for the duration of the agreement, grant disbursement and 7 years after plant commissioning
-
Effective Malaysian equity, GNI and jobs should be reported 7 years after plant commissioning on an annual basis
|
| |
|
|
| (B) |
Clinical Research |
| |
Type of study: |
| |
|
|
| |
|
|
| |
Researcher: |
| |
|
|
APPLICATION PROCESS FLOW
|
| |
|
| (A) |
Commercialization Projects: |
| |
Step 1: Application:
|
| |
|
-
Please download the form, fill in the details and send it to
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
-
Notification will be provided should the project successfully proceed to the next round of evaluation
|
| |
|
|
| |
Step 2: Evaluation Rounds: |
| |
|
-
Company will be required to present their case upon notification for a few occasions, documents will also be required upon request
-
1st Round will be several internal evaluation rounds
- 2nd Round - Technical Committee chaired by DG of MPOB
- 3rd Round - Steering Committee chaired by Minister
|
| |
|
|
| |
Step 3: Notification of Application Status |
| |
|
|
| (B) |
Clinical Research |
| |
Step 1: Application: |
| |
|
|
| |
|
|
| |
Step 2: Evaluation Rounds: |
| |
|
- 3rd Round - Steering Committee chaired by Minister
|
| |
|
|
| |
Step 3: Notification of Application Status
|
|
